Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment

Last updated: May 4, 2023
Sponsor: Regina Elena Cancer Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Myeloma

Cancer/tumors

Lymphoproliferative Disorders

Treatment

ATAC-seq and ChIP-seq

Clinical Study ID

NCT05858203
RS1442/20
  • All Genders

Study Summary

Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of proliferating antibody producing plasma cells in the bone marrow. In the last few years many studies have emphasized the biological complexity and heterogeneity of MM as a result of both genetic and epigenetic aberrations. Che-1/AATF (Che-1) is a transcriptional cofactor involved in cell cycle regulation, apoptosis, DNA damage and stress response. it can be hypothesized that Che-1 might contribute to the establishment of the MM malignant phenotype by sustaining global transcription through its ability to modulate chromatin accessibility.

The prospective study on MM human samples aims to understand the involvement of Che-1 in the transcriptional regulation and chromatin remodeling during the pathology. To this goal the main objectives are:

  • Characterization of Che-1's role in chromatin remodeling and global gene expression

  • Study in vivo and in vitro of Che-1 involvement in MM tumorigenesis

  • Evaluation of Che-1 as a possible therapeutic target

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • MM Patients

Exclusion

Exclusion Criteria:

  • No exclusion criteria

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: ATAC-seq and ChIP-seq
Phase:
Study Start date:
December 22, 2020
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Regina elena Cancer Institute

    Roma, 00144
    Italy

    Site Not Available

  • "Regina Elena" National Cancer Institute

    Rome, 00144
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.